Buprenorphine Dosing Interval - 5
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000209
Collaborator
(none)
0
1
Study Details
Study Description
Brief Summary
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Masking:
Single
Primary Purpose:
Treatment
Official Title:
Buprenorphine Dosing Interval
Study Start Date
:
Nov 1, 1992
Outcome Measures
Primary Outcome Measures
- Drug use []
- Withdrawal symptoms []
- Opiate and cocaine craving []
Eligibility Criteria
Criteria
Ages Eligible for Study:
21 Years
to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Friends Research Institute | Los Angeles | California | United States | 90025 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
Investigators
- Principal Investigator: Walter Ling, M.D., Friends Research Institute, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000209
Other Study ID Numbers:
- NIDA-06082-5
- R18-06082-5
First Posted:
Sep 21, 1999
Last Update Posted:
Aug 17, 2005
Last Verified:
Sep 1, 1994